Prostate cancer is the most commonly diagnosed cancer in men — approximately 250,000 American men receive the diagnosis each year. It is also one of the most overtreated. The conversation most men have with their urologist covers what was found and what can be done about it. It rarely covers the full picture of what a diagnosis actually means, what the test limitations are, or what the options are beyond the ones being offered.
What PSA Actually Measures
Prostate-Specific Antigen (PSA) is a protein produced by the prostate gland. An elevated PSA can indicate cancer — but it can also indicate benign prostatic hyperplasia (BPH), prostatitis, a recent prostate exam, recent ejaculation, or a urinary tract infection. PSA is not a cancer test. It is a prostate stress test.
What you were not told about PSA
The U.S. Preventive Services Task Force (USPSTF) previously recommended against routine PSA screening for men over 70 due to the high rate of overdiagnosis and overtreatment — and revised its guidance to note that for men aged 55–69, the decision should be individualized and based on a full discussion of harms. Many men are screened without this discussion.
PSA velocity (how fast it is rising) and PSA density (PSA relative to prostate volume) are more informative than a single number — but a single elevated number frequently triggers immediate biopsy referral without these additional measures being calculated.
Finasteride and dutasteride (prescribed for BPH and hair loss) reduce PSA by approximately 50%. A man on these medications with a PSA of 2.5 has a true PSA equivalent closer to 5.0. This adjustment is recommended in guidelines but frequently not made in clinical practice — meaning cancer can be missed, or the significance of a rising number misread.
Gleason Score and What It Actually Means
The Gleason score grades prostate cancer from 6 to 10 based on how aggressive the cells look under a microscope. This is the number that drives treatment urgency — and it is the number most men are not fully educated on before treatment decisions are made.
The overtreatment problem
The majority of prostate cancer diagnoses are Gleason 6 (low grade) or Gleason 3+4 (favorable intermediate). The landmark ProtecT trial — a 15-year randomized controlled trial comparing surgery, radiation, and active monitoring — found no significant difference in prostate cancer mortality across all three approaches for men with localized disease. Men were dying with prostate cancer, not from it. The differences were in side effects and quality of life. Surgery and radiation produced significantly more urinary, bowel, and sexual side effects than monitoring. This trial is rarely the centerpiece of the treatment conversation.
Risk stratification: the three-tier decision framework
Not all prostate cancer is the same disease, and not all prostate cancer requires the same response. Oncologists who specialize in prostate cancer — including Dr. Mark Scholz, a medical oncologist with decades of prostate cancer practice and co-author of Invasion of the Prostate Snatchers — use a three-tier risk framework that maps directly to treatment urgency. The urgency framing that permeates most urology appointments is drawn from the high-risk tier and applied to all three.
Low-Risk (Gleason 6, PSA below 10, limited biopsy involvement): No immediate treatment required. Active surveillance is the evidence-based standard of care. Immediate intervention trades side effects for no survival benefit in this group.
Intermediate-Risk (Gleason 7, or PSA 10–20, or specific staging findings): Evaluation for treatment may be appropriate, depending on whether disease is favorable or unfavorable intermediate-risk and on tumor biology. Genomic testing is most valuable in this group before any decision is made.
High-Risk (Gleason 8–10, PSA above 20, or T3–T4 staging): Immediate treatment with a combination of therapies is genuinely warranted. This is a minority of prostate cancer diagnoses.
Staging: What It Means That the Cancer Is Outside the Prostate
Prostate cancer is staged using the TNM system — Tumor, Nodes, Metastasis. The T stage describes where the primary tumor is and whether it has crossed anatomical boundaries. The N and M designations describe spread to lymph nodes and distant sites. This is the framework that drives treatment recommendations — but the nuances within each stage are rarely explained.
N and M staging: when the cancer has left the prostate region
N0 / N1: N0 means no regional lymph node involvement. N1 means cancer has spread to pelvic lymph nodes. N1 disease significantly changes treatment options and prognosis — radical surgery is typically no longer the primary recommendation, and systemic therapy becomes central.
M0 / M1: M0 means no distant metastasis. M1a is non-regional lymph nodes. M1b — the most common distant site — is bone. Prostate cancer has a particular predilection for the axial skeleton (spine, pelvis, ribs) because of Batson's plexus, the valveless venous network surrounding the prostate with direct connections to the vertebral venous system. M1c is other distant organ involvement (liver, lung). M1 disease is metastatic and is treated with systemic therapy; local treatment to the prostate itself may still be offered in specific protocols but does not constitute a cure.
Why T3 changes everything about procedures
Once the capsule is breached, the clean anatomical boundaries that surgical planning depends on no longer exist. Positive surgical margins are significantly more common in T3 disease — meaning cancer cells at the cut edge, requiring additional treatment. Nerve-sparing is contraindicated where the tumor abuts the neurovascular bundle. And for TURP specifically, T3 disease means the cancer is already adjacent to the same venous sinuses that TURP deliberately opens — raising the concern that mechanical disruption during the procedure could directly introduce cancer cells into Batson's plexus and the systemic circulation. This concern is discussed further in the Biopsy & TURP tab.
Genomic testing: the step most men are not offered
Genomic tests (Decipher, Prolaris, Oncotype DX Genomic Prostate Score) analyze the tumor's molecular signature and provide a more precise picture of biological aggressiveness than Gleason grade alone. For men with intermediate-risk disease deciding between immediate treatment and active surveillance, these tests can fundamentally change the decision. They are not routinely offered. Ask specifically whether genomic testing has been considered before committing to an irreversible treatment path.
The Prostate Biopsy: What Is Not Disclosed
A prostate biopsy involves inserting a needle — typically 12 times in a systematic transrectal approach — through the rectal wall into the prostate gland to collect tissue samples. The procedure is scheduled and performed quickly, often before patients have time to research what it involves.
Needle Tract Seeding
Needle tract seeding refers to the displacement of cancer cells along the path of the biopsy needle as it is withdrawn. This is a documented phenomenon in prostate and other organ biopsies. The mechanical disruption of the tumor deposits cancer cells in tissue that was previously uninvolved. This risk is present with any percutaneous biopsy of a solid tumor and is rarely mentioned in the consent conversation for prostate biopsy.
Transrectal Biopsy and Sepsis Risk
The standard transrectal ultrasound-guided (TRUS) biopsy passes the needle through the rectal wall — introducing gut bacteria directly into the prostate and bloodstream. Infection rates following TRUS biopsy range from 1–7%, including cases of life-threatening sepsis. As fluoroquinolone-resistant bacteria have become more prevalent, the rate of post-biopsy sepsis hospitalizations has risen. This risk is frequently disclosed only as a minor footnote, if at all.
Transrectal vs. Transperineal: a choice rarely offered
The transperineal approach — where the needle passes through the perineal skin rather than the rectal wall — has a dramatically lower infection and sepsis rate than transrectal biopsy. Infection rates with transperineal approach are consistently below 0.5% in published series vs. 1–7% for transrectal. The transperineal approach is standard in some European countries and is increasingly available in the US. Most men are not told this option exists, nor told that the infection risk profile is meaningfully different.
MRI-targeted biopsy (MRI-TRUS fusion) — in which a pre-procedure MRI identifies suspicious lesions and the biopsy is guided directly to those areas — detects more clinically significant cancers and fewer indolent low-grade cancers than systematic 12-core biopsy. It also reduces the number of needle passes required. Ask specifically whether MRI-guided targeted biopsy is available before agreeing to a systematic approach.
TURP: The Procedure That Opens Vascular Channels Inside a Cancerous Prostate
Transurethral resection of the prostate (TURP) is a surgical procedure in which a resectoscope is passed through the urethra and used to shave away prostate tissue from the inside. It is performed for urinary obstruction — it is not a cancer treatment and does not remove the entire prostate. In men with prostate cancer who develop significant urinary retention, TURP is sometimes offered as a palliative measure to restore urine flow.
The informed consent gap with TURP in the context of prostate cancer is specific, anatomical, and serious.
Batson's Plexus and the Cancer Cell Dissemination Concern
The prostate sits within a rich network of valveless veins called the Batson's plexus, which connects directly to the vertebral venous system — the vascular network feeding the spine and bones. This connection is not incidental. It is the anatomical reason prostate cancer preferentially metastasizes to the axial skeleton. Cancer cells released into the prostatic venous plexus travel directly toward the vertebrae and pelvis through a system that has no valves to slow or redirect them.
During TURP, the surgeon deliberately opens venous sinuses throughout the prostate in order to resect tissue. In a prostate that contains cancer — particularly stage 3 disease where the capsule has already been breached — these open venous channels are running directly through and adjacent to cancerous tissue. The theoretical and documented concern is that mechanical disruption of the prostate during TURP releases cancer cells into this vascular system at the exact point where they have direct access to the systemic circulation and to Batson's plexus.
Published literature has examined circulating tumor cell (CTC) counts and PSA changes following TURP in cancer patients. The data is mixed — some studies show no significant long-term oncological harm, others raise concern about accelerated biochemical recurrence. What is clear is that this risk is almost never disclosed to men with prostate cancer before a TURP is scheduled. The procedure is presented purely as symptom management.
Alternatives to TURP for urinary obstruction in prostate cancer
Hormonal volume reduction — LHRH agonists (Lupron) or LHRH antagonists (Orgovyx) reduce prostate volume by suppressing testosterone; urinary obstruction often resolves within weeks; this is a reasonable first step before considering TURP in men with hormone-sensitive disease
Suprapubic catheter — provides urine drainage without entering the prostate; appropriate for acute retention while systemic treatment is initiated
GreenLight laser (PVP) — less blood loss than TURP; whether it reduces cancer cell dissemination risk is unknown; see expanded discussion below
Urethral stenting — temporary stent placement to maintain urinary flow without prostate resection; less commonly used but available
GreenLight Laser (PVP): The "Less Invasive" Alternative That Carries Its Own Gaps
Photoselective vaporization of the prostate (PVP) — marketed under the GreenLight brand — uses a 532nm laser whose energy is selectively absorbed by oxyhemoglobin in the blood-rich prostate tissue. Rather than cutting and removing tissue as TURP does, the laser vaporizes it. The result is less intraoperative bleeding, shorter catheterization time, and an outpatient-capable procedure. For men on anticoagulants who cannot safely undergo TURP, GreenLight is frequently the alternative offered.
What the marketing does not say
Retrograde ejaculation: GreenLight produces retrograde ejaculation in approximately 50–70% of men — higher than TURP in some series. This is almost never part of the pre-procedure consent conversation, particularly because the procedure is framed as "minimally invasive."
Durability: Long-term re-treatment rates with GreenLight are higher than with TURP in multiple studies at the 5–10 year mark. The symptom relief that drove the procedure may require repeating. Men are rarely told this when GreenLight is presented as the superior option.
Post-procedure irritative symptoms: Urinary urgency, frequency, and dysuria in the weeks following PVP are common and can be significant — often more pronounced than after TURP in the immediate recovery period.
The cancer cell dissemination question — unanswered
GreenLight is frequently presented to men with prostate cancer as a safer alternative to TURP specifically because it is "less invasive" and produces less bleeding. The assumption embedded in this framing is that less bleeding means less vascular disruption — and therefore less risk of cancer cell entry into Batson's plexus.
This assumption has not been validated. The laser vaporizes tissue by superheating it through vascular absorption — the mechanism of tissue destruction runs directly through the blood vessels in the prostate wall. In a cancer-containing prostate, those blood vessels are adjacent to or within tumorous tissue. The thermal disruption zone extends beyond the visible vaporization boundary. Whether this mechanism releases fewer viable cancer cells into the prostatic venous plexus than TURP's mechanical resection is unknown — there are no prospective trials specifically examining GreenLight PVP outcomes in men with concurrent prostate cancer.
The absence of data is not the same as absence of risk. A man with prostate cancer being offered GreenLight as a "safer" alternative to TURP deserves to know that the oncological safety comparison between the two procedures has not been studied in this specific population.
Biopsy Risks Across Other Organs
Needle tract seeding is not unique to prostate biopsy. The same concern exists for liver biopsy in hepatocellular carcinoma (HCC), where peritoneal seeding and chest wall implantation following biopsy are documented — and where a prior biopsy can disqualify a patient from liver transplant eligibility. Lung biopsy carries pneumothorax rates of 25–30%, with a meaningful percentage requiring chest tube placement. Liver biopsy carries a procedural mortality of approximately 1 in 1,000–3,000 procedures from hemorrhage.
In every case, the mechanical disruption of a tumor by a needle creates a theoretical and sometimes documented pathway for cells that were contained to enter tissue and circulation where they were not. This conversation should happen before any tumor biopsy — not after.
Radiation therapy for prostate cancer comes in several forms: external beam radiation therapy (EBRT), intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT/SABR), and brachytherapy (seed implants — LDR — or high-dose rate — HDR). The choice between these is presented as a technical matter. The informed consent about long-term consequences is often not.
What Is Not Disclosed: Late Effects
Acute side effects of prostate radiation — urinary frequency, urgency, rectal irritation — are typically disclosed as temporary. What is less consistently disclosed are the late and permanent effects that emerge months to years after treatment concludes.
Radiation Proctitis
Radiation proctitis occurs when the rectal wall is damaged by radiation scatter from prostate treatment. Mild cases involve intermittent rectal bleeding and urgency. Severe cases involve chronic bleeding, painful urgency, incontinence, and — in the most serious presentations — rectal fistula (an abnormal connection between the rectum and another structure, including the bladder or skin). Fistula formation is rare but devastating and requires surgical repair. Chronic radiation proctitis that does not respond to medical management may require hyperbaric oxygen therapy, argon plasma coagulation, or surgical intervention. This trajectory — from "mild rectal irritation" at the time of consent to years of bleeding and procedural management — is not part of the standard pre-treatment conversation.
Secondary Malignancies
Radiation-induced secondary cancers: the undisclosed long-term risk
Ionizing radiation causes DNA damage not only in the target tissue but in surrounding structures. Long-term follow-up studies of men treated with prostate radiation show elevated rates of bladder cancer and rectal/colorectal cancer in the years and decades following treatment. The relative risk elevation varies by study but is consistently present in long-term data. For a 65-year-old man with a 20-year life expectancy, this is a meaningful consideration.
This risk is not listed on most pre-treatment consent forms in a way that is legible to a patient. It appears in the prescribing literature and in long-term follow-up studies. Men are rarely handed those studies at the time of treatment decision.
Proton Beam Therapy: The Marketing vs. The Evidence
Proton beam therapy is marketed aggressively as a more precise, gentler form of radiation that delivers energy directly to the tumor with less damage to surrounding tissue (the Bragg peak). Proton beam centers are expensive to build and operate — costs that are recovered through high reimbursement for each treated patient. The clinical evidence for proton beam's superiority over modern IMRT for prostate cancer — in terms of cancer control, long-term side effects, or quality of life — is limited. Comparative effectiveness studies and systematic reviews have generally not found meaningful outcome differences that justify the substantially higher cost and the geographic concentration of these centers. The financial incentive to fill proton beam machines is significant, and patients should understand that the enthusiasm of a proton beam center for treating their cancer may not be driven entirely by clinical evidence.
When ADT Is Added to Radiation
For intermediate and high-risk prostate cancer, radiation is frequently combined with androgen deprivation therapy (ADT) — hormone therapy that drives testosterone to castrate levels. Adding ADT to radiation improves cancer outcomes for certain risk groups. It also adds a separate layer of toxicity that is frequently underemphasized in the consent conversation for radiation. The side effects of ADT are not mild and not short-term. They are detailed on the Drug Library pages for leuprolide, degarelix, and relugolix — and include cardiovascular risk, bone density loss, muscle wasting, cognitive decline, metabolic syndrome, and complete loss of sexual function.
When radiation fails: the salvage problem
Biochemical failure (rising PSA after radiation) occurs in a meaningful percentage of men and indicates the cancer has recurred. Salvage options after radiation failure are significantly more limited and more dangerous than salvage after surgery failure. Salvage prostatectomy — surgery after prior radiation — carries dramatically higher complication rates than primary surgery: higher rates of incontinence, anastomotic stricture, rectal injury, and fistula. The radiation has altered tissue planes and blood supply in ways that make surgery technically far more difficult. This sequencing consideration — that the choice of primary treatment affects future options — is rarely part of the initial consent conversation.
Radical prostatectomy — surgical removal of the entire prostate gland — is the other major primary treatment for localized prostate cancer. It is offered alongside radiation, and the choice between them is frequently influenced by the specialty of the physician you see first: urologists tend to refer to surgery, radiation oncologists to radiation. Neither specialist has a financial incentive to send you to the other.
The conflict of interest in numbers
Dr. Mark Scholz — a medical oncologist specializing in prostate cancer and co-author of Invasion of the Prostate Snatchers — documents that virtually all physicians treating prostate cancer are either surgeons or radiation therapists. Medical oncologists without procedural income tied to surgery or radiation represent a small fraction of the prostate cancer treatment landscape. The financial incentive of the recommending physician is structurally built into the specialty.
A study in the New England Journal of Medicine examining radical prostatectomy outcomes concluded that of approximately 50,000 radical prostatectomies performed annually in the United States, the majority were not justified by evidence of survival benefit. For most men with localized disease — particularly low and favorable intermediate-risk — the operation does not meaningfully extend life. What it reliably does do is alter quality of life, in many cases permanently.
What Surgery Actually Involves
Radical prostatectomy removes the prostate, the seminal vesicles, and typically the pelvic lymph nodes. It requires general anesthesia. The urethra is then reconnected to the bladder (urethrovesical anastomosis). Recovery involves a catheter for 1–2 weeks. The surgery is performed open, laparoscopically, or robotically — the last being the dominant approach in the US.
Robotic Surgery: What the Marketing Does Not Say
Robotic-assisted prostatectomy (da Vinci system) is marketed with images of precision, smaller incisions, and faster recovery. Hospitals invest millions in robotic surgery equipment and recover this investment through surgical volume. The evidence on whether robotic prostatectomy produces better oncological outcomes — margin rates, biochemical recurrence, survival — than open or laparoscopic surgery, when performed by a skilled surgeon, is mixed. What the evidence does show clearly is that outcomes are strongly surgeon-volume dependent. A high-volume urologist with an open approach outperforms a low-volume surgeon with a robot. The robot is a tool. The question to ask is how many of these procedures the specific surgeon performing yours has done — not which machine they are using.
Urinary Incontinence and Erectile Dysfunction
Side effect rates at 5 years: what the consent form often does not convey
Urinary incontinence: Rates vary widely based on how "continence" is defined. Studies using the strictest definition (no pads required) find persistent incontinence in 15–30% of men at 1–2 years post-surgery. Studies using looser definitions report better numbers. Ask your surgeon how they define continence and what their personal patient outcomes data shows — not the published average.
Erectile dysfunction: More than half of men who undergo radical prostatectomy will not recover satisfactory erectile function. Nerve-sparing surgery attempts to preserve the neurovascular bundles running alongside the prostate, and in the best-case scenario — younger man, normal pre-operative function, bilateral nerve-sparing, high-volume surgeon — recovery rates can reach 60–70%. In real-world outcomes across the full surgical population, the persistent erectile dysfunction rate at 2 years exceeds 50%. Nerve-sparing is not possible when the cancer is at or near the capsule on that side — and many men are told "nerve-sparing" without being told what that means when the tumor anatomy does not allow it.
Positive Surgical Margins and Biochemical Recurrence
A positive surgical margin means cancer cells were found at the cut edge of the removed specimen — indicating cancer was left behind in the body. Positive margin rates in radical prostatectomy range from 10–40% depending on disease stage, surgeon experience, and tumor location. A positive margin often triggers adjuvant or salvage radiation, which then creates the combined side effect burden of both treatments.
Biochemical recurrence (PSA rising after surgery) occurs in approximately 20–30% of men at 10 years following radical prostatectomy. It is a sign the cancer has returned — either locally or systemically — and typically leads to additional treatment. The surgery is not a guarantee of cure, and this probability is not always communicated with the clarity it deserves.
The Treatment Sequencing Problem
If surgery fails and PSA rises, the next step is typically salvage radiation. If radiation fails after surgery, options remain. But if radiation is chosen first and fails, salvage surgery carries dramatically higher complication rates than primary surgery — because radiation has altered tissue, blood supply, and surgical planes. This asymmetry in future options — surgery first preserves radiation as a future tool; radiation first makes future surgery much harder — is rarely part of the initial treatment choice conversation.
Prostate conditions involve two largely separate drug landscapes: medications for urinary symptoms from benign prostate enlargement (BPH), and medications used in prostate cancer treatment. The informed consent gaps in both categories are significant.
BPH Drugs: What Is Not Disclosed
Alpha Blockers (tamsulosin / Flomax, silodosin / Rapaflo, doxazosin / Cardura, alfuzosin / Uroxatral)
Alpha blockers relax smooth muscle in the prostate and bladder neck to improve urine flow. They do not shrink the prostate or address the underlying cause of enlargement. Two critical disclosures are routinely missing from the prescribing conversation:
Intraoperative Floppy Iris Syndrome (IFIS): a vision-threatening surgical risk
Alpha blockers — all of them, including tamsulosin (Flomax), silodosin (Rapaflo), alfuzosin (Uroxatral), and doxazosin (Cardura) — permanently alter iris muscle tone. During cataract surgery, this causes the iris to become flaccid and prolapse out of the incision, creating a risk of hemorrhage, posterior capsule rupture, and permanent vision damage. This risk persists even after stopping the drug. Every man on any alpha blocker must disclose this to their ophthalmologist before any eye surgery. This warning is frequently absent from the prescribing conversation entirely.
Silodosin (Rapaflo) also carries the highest rate of retrograde ejaculation of any drug in this class — up to 20–28% of users — in which semen enters the bladder during orgasm rather than exiting normally. This is not dangerous but affects fertility and is very rarely disclosed upfront.
Finasteride and Dutasteride: Post-Finasteride Syndrome and PSA Masking
Finasteride (Proscar) and dutasteride (Avodart) shrink the prostate by blocking the conversion of testosterone to DHT. They are also prescribed at lower doses for male pattern hair loss (Propecia). What most men are not told:
Post-finasteride syndrome: A subset of men who take finasteride or dutasteride develop persistent erectile dysfunction, loss of libido, inability to orgasm, genital numbness, depression, cognitive impairment, and neurological symptoms that continue after stopping the drug — sometimes indefinitely. The FDA updated the prescribing label in 2011 to include persistent sexual adverse effects. Many prescribers still present this as a low-risk medication.
PSA masking: These drugs reduce PSA by approximately 50%. A man with a PSA of 2.5 while on finasteride may have a true PSA equivalent of 5.0. If the prescriber does not double the PSA for interpretation purposes, prostate cancer can be missed entirely — or the significance of a rising PSA underestimated.
High-grade cancer signal: The PCPT trial (NEJM, 2003) found that while finasteride reduced overall prostate cancer incidence, men who developed cancer on finasteride had higher rates of Gleason 7–10 (high-grade) cancer. This finding is still debated but must be part of the consent conversation.
Dutasteride half-life: Dutasteride has a 5-week half-life and remains active in the body for months after the last dose. Any persistent side effects after stopping may take far longer to resolve than with finasteride — or may not resolve.
ADT: Androgen Deprivation Therapy
LHRH agonists (leuprolide/Lupron, goserelin/Zoladex) and LHRH antagonists (degarelix/Firmagon, relugolix/Orgovyx) drive testosterone to castrate levels — the cornerstone of advanced and high-risk prostate cancer treatment. The side effects of ADT are extensive and frequently minimized at the time of prescribing.
The ADT side effects most often underdisclosed
Cardiovascular risk: The FDA issued a class warning in 2010 that GnRH agonists increase risk of myocardial infarction, sudden cardiac death, stroke, and diabetes. Men with pre-existing cardiovascular conditions face the highest risk. Relugolix (Orgovyx) — the oral antagonist — showed significantly lower cardiovascular event rates than leuprolide in the HERO trial and is now the preferred ADT option for men with cardiac history. Most men are defaulted to Lupron injections without this option being discussed.
Dementia and cognitive decline: Multiple large cohort studies — including studies published in JAMA Internal Medicine — have found significantly elevated rates of Alzheimer's disease and dementia in men on longer-duration ADT. The risk increases with duration of treatment. This is almost never disclosed.
Osteoporosis and fracture: Castrate testosterone causes rapid bone density loss. Men on ADT for 12 months lose bone density at rates exceeding that of postmenopausal women. Bone density scans and bone-protective medications should be offered routinely — they often are not.
Testosterone flare with LHRH agonists: Leuprolide and goserelin initially cause a testosterone surge before suppression begins. In men with metastatic bone disease, this flare can precipitate a bone pain crisis or spinal cord compression. Anti-androgen coverage (bicalutamide) for the first 2–4 weeks is standard of care — if it was not prescribed, the consent was incomplete.
Testosterone recovery: A significant percentage of men on prolonged ADT never return to pre-treatment testosterone levels after stopping. The timeline and probability of recovery should be discussed before ADT is initiated, particularly for men who will be on treatment for more than 6 months.
Anti-Androgens: Seizure Risk and Enzyme Induction
The next-generation anti-androgens — enzalutamide (Xtandi) and apalutamide (Erleada) — are potent androgen receptor blockers used in advanced prostate cancer. Both cross the blood-brain barrier and carry seizure risk. Enzalutamide carries approximately 1% seizure risk; it is contraindicated in men with prior seizure disorders and carries driving restrictions that are rarely communicated. Both drugs are also strong enzyme inducers that significantly reduce the blood levels of many other medications — warfarin, statins, thyroid hormone, and others. A full drug interaction review is essential before starting either drug and whenever any other medication is added.
Abiraterone: the prednisone requirement and adrenal crisis risk
Abiraterone (Zytiga, Yonsa) blocks testosterone synthesis in the adrenal glands and tumor cells. It must always be taken with a corticosteroid (prednisone or methylprednisolone) because it also suppresses cortisol production. Stopping prednisone while on abiraterone — due to a prescription lapse, a hospitalization, or simply forgetting — can precipitate acute adrenal insufficiency. Emergency medical providers must know this drug requires steroid coverage. Men should carry medical ID indicating this requirement. This is frequently not explained at prescribing.
Testosterone, DHEA, and Bioidentical Hormones
Many men with prostate cancer — particularly those on or considering ADT — ask about testosterone replacement, DHEA, or bioidentical hormone therapy. This is a clinically complex area where the standard narrative has shifted substantially, and where the informed consent conversation rarely happens at all.
What the research actually shows
The Huggins dogma: Charles Huggins' 1941 work showed that castration caused prostate cancer regression and that testosterone administration caused progression. This became dogma: testosterone feeds prostate cancer. It is still the operating assumption in most oncology practice.
The saturation model: Work by Abraham Morgentaler and colleagues, beginning in the 1990s, challenged the linear androgen-cancer relationship. The saturation model proposes that androgen receptors on prostate cells become saturated at relatively low testosterone levels — and that above that saturation point, additional testosterone does not further stimulate cancer growth. The implication: the castrate-to-normal range matters enormously; normal-to-supraphysiological may not. This model is not universally accepted, but it has substantial published support and is the theoretical basis for the small trials of testosterone therapy in men with low-risk localized prostate cancer on active surveillance.
Aromatization: Exogenous testosterone is aromatized to estradiol. In men with prostate cancer, estrogen's role is complex — estrogen receptors are present in prostate tissue, and estrogen is not uniformly protective. The net effect of testosterone supplementation on intraprostatic estrogen milieu in a cancer-bearing prostate is not fully characterized.
DHT conversion: Testosterone is converted to dihydrotestosterone (DHT) by 5-alpha reductase — DHT is the primary androgen driving prostate cell proliferation. Supplemented testosterone increases the substrate for DHT synthesis. This is why 5-ARI drugs (finasteride, dutasteride) are used in BPH: they block this conversion. The DHT implications of testosterone supplementation in men with cancer are rarely fully discussed.
DHEA conversion unpredictability: DHEA is sold over the counter and widely perceived as a mild, safe supplement. In the body, DHEA converts to both testosterone and estrogens — in proportions that vary substantially by individual based on enzyme activity, body composition, and age. The downstream hormonal effect of supplementing DHEA in a man with prostate cancer cannot be predicted from the dose taken. This is not disclosed on product labels.
Bioidentical forms vs. synthetic esters: Bioidentical testosterone (same molecular structure as endogenous testosterone — cypionate and enanthate esters deliver the same bioidentical molecule) is metabolized identically to endogenous testosterone. The distinction between "bioidentical" and "synthetic" in terms of cancer risk is not established in the prostate cancer literature — the risk considerations around aromatization and DHT conversion apply equally.
What you should know before taking any androgenic hormone product with prostate cancer
No large randomized trial has established the safety of testosterone supplementation in men with prostate cancer. Existing data comes from small, selected series in low-risk localized disease. Extrapolating to intermediate-risk, high-risk, post-treatment recurrence, or metastatic disease is not supported.
Men with undetected prostate cancer who begin testosterone therapy may see PSA rise as the first detectable signal — or may not, if the cancer has lost androgen sensitivity. A rising PSA on testosterone does not necessarily indicate cancer progression; an unchanged PSA does not rule out progression.
The ADT-hormone replacement paradox: Men who have had their testosterone driven to castrate levels by ADT and then consider testosterone supplementation to recover quality of life face a situation where their oncologist is simultaneously suppressing the hormone another provider is prescribing. This conflict requires direct coordination.
Glutathione IV and Transdermal: The Metastasis Question
Glutathione IV infusions and transdermal glutathione have become widely used in functional and integrative medicine — promoted for detoxification, anti-aging, immune support, and as supportive care during cancer treatment. In men with active prostate cancer, this requires a more careful conversation than typically happens.
The mechanism of concern
Cancer cells upregulate glutathione: It is well-established that cancer cells — including prostate cancer cells — upregulate intracellular glutathione and glutathione peroxidase (GPx) as a survival strategy. GPx expression is elevated in aggressive prostate cancer. Glutathione allows cancer cells to neutralize the reactive oxygen species (ROS) generated by chemotherapy, radiation, and the body's own immune attack.
Circulating tumor cells and oxidative stress: When prostate cancer cells detach and enter the bloodstream as circulating tumor cells (CTCs), they face a hostile oxidative environment. Plasma is rich in ROS; the vast majority of CTCs die before reaching a secondary site. This oxidative death of CTCs is a natural anti-metastatic mechanism.
The antioxidant-metastasis data: A 2015 study by Villanueva and colleagues (Nature Medicine) found that supplementing NAC (N-acetylcysteine) and vitamin E — both antioxidants — in mouse models of melanoma significantly increased the number of distant metastases by protecting CTCs from oxidative destruction in transit. A subsequent study found similar effects on circulating melanoma cell invasiveness. Glutathione is a more direct antioxidant than either NAC or vitamin E, and glutathione precursor supplementation (NAC is one) raises intracellular GSH. The mechanistic pathway from IV glutathione to enhanced CTC survival is plausible and not experimentally excluded.
What the direct human data does and does not show: There are no large RCTs of glutathione supplementation in prostate cancer patients showing increased metastasis. The Villanueva data is animal-model. However, the absence of human evidence of harm is not the same as established safety — and the biological mechanism is coherent with what is known about how CTCs die and how glutathione protects cells from oxidative death.
The context matters
Active disease with CTC potential: Men with intermediate or high-risk disease, biochemical recurrence, or known metastatic disease are most likely to have circulating tumor cells. These are the men for whom the theoretical metastasis concern carries the most weight.
During radiation or chemotherapy: Radiation and chemotherapy work partly by generating ROS to kill cancer cells. High-dose antioxidant supplementation during active treatment may partially antagonize treatment effect. This concern is separate from the CTC mechanism — and equally underdisclosed.
Post-treatment, stable, undetectable PSA: The concern is lower in men who have completed definitive treatment with no evidence of disease. The CTC question is most relevant when active disease is present or likely.
This is not a settled question. It is an open mechanistic concern that integrative practitioners offering glutathione IV to cancer patients should disclose — and frequently do not.
Full drug entries for every prostate medication — including excipients, interactions, and the full informed consent picture — are available in the Drug Library under the Prostate filter.
What the ProtecT Trial Found
The ProtecT trial is a landmark 15-year randomized controlled trial from the United Kingdom that enrolled over 1,600 men with localized prostate cancer and randomized them to radical prostatectomy, radiation therapy, or active monitoring. The 15-year results found no significant difference in prostate cancer mortality between the three groups. Men were dying with prostate cancer, not from it. What the groups did differ significantly on was quality of life: surgery produced higher rates of urinary incontinence and erectile dysfunction; radiation produced higher rates of bowel symptoms and erectile dysfunction; active monitoring produced more anxiety and more men who eventually needed treatment — but more years of preserved function in the interim.
What active surveillance looks like in practice
PSA testing every 3–6 months
Digital rectal exam annually
Repeat biopsy at 12 months to confirm Gleason grade; subsequent biopsies based on PSA trajectory and MRI findings
MRI at intervals to assess tumor volume and characteristics
Defined triggers for moving to active treatment: grade progression, PSA doubling time below a threshold, patient preference
Who Active Surveillance Is Appropriate For
Active surveillance is the standard of care recommendation (per NCCN guidelines) for men with very low-risk and low-risk prostate cancer — Gleason 6, PSA below 10, limited biopsy involvement. It is also appropriate for many men with favorable intermediate-risk disease (Gleason 3+4, limited tumor burden). Genomic testing (Decipher, Prolaris, Oncotype DX) can help identify men in the intermediate-risk group whose tumor biology is truly low-risk and for whom surveillance remains appropriate.
Gleason 6: Is It Even Cancer?
A growing body of pathology literature argues that Gleason 6 prostate cancer does not behave biologically like cancer. There are no documented cases of Gleason 6 prostate cancer metastasizing in the published literature. Some researchers and pathologists have proposed reclassifying Gleason 6 as a low-malignant-potential lesion rather than cancer — arguing that attaching the word "cancer" to a condition that has never been shown to spread or kill creates unjustified treatment urgency. This debate is ongoing and unresolved. What is not debated is that Gleason 6 is the least dangerous end of the prostate cancer spectrum and that most men with Gleason 6 diagnosed in their 60s will die of something entirely unrelated.
The overtreatment data
Multiple modeling studies estimate that a substantial proportion of prostate cancers detected through PSA screening — particularly in older men — represent overdiagnosis: cancers that would never have caused symptoms or death in the patient's remaining lifetime. These men receive surgery or radiation that affects their quality of life, carries procedural risks, and in some cases causes long-term complications — for a condition that would not have harmed them. This is not a fringe view. It is the basis for the USPSTF's screening recommendations and for the active surveillance protocols now endorsed by every major urological organization.
The Psychological Reality
Living with a cancer diagnosis and not treating it is psychologically difficult for many men and their families. This is real and should not be dismissed. The anxiety is documented — men on active surveillance report higher cancer-related anxiety than men who chose immediate treatment. What active surveillance programs have found, however, is that this anxiety diminishes significantly over time as men accumulate stable PSA results and understand their tumor's trajectory. The psychological burden of incontinence and erectile dysfunction after unnecessary treatment for a cancer that would never have progressed is its own lasting harm.
The standard prostate cancer appointment is structured around what the physician recommends. These questions are structured around what you were not asked, and what you have a right to know before you consent to anything.
Before a Biopsy
Is this biopsy transrectal or transperineal? What is your infection rate with the approach you're recommending? Have you considered transperineal given the lower sepsis risk?
Is there an MRI-targeted (fusion) biopsy option? Has an MRI been done to identify suspicious lesions before sampling?
What is my actual risk of prostate cancer given my PSA, PSA velocity, PSA density, age, and family history? Is biopsy the right next step, or is there more information we should gather first?
What is the risk of needle tract seeding with this procedure?
If I am on finasteride or dutasteride — has my PSA been doubled for interpretation?
Before a TURP
I have prostate cancer. What is the risk that this procedure could release cancer cells into my bloodstream through the prostatic venous system?
Has hormonal volume reduction been tried or considered to reduce the prostate and relieve obstruction before TURP is performed?
Is a suprapubic catheter or other non-resective approach appropriate while we explore medical options?
What is the literature on TURP outcomes in stage 3 prostate cancer specifically?
If GreenLight laser is being offered as a "safer" alternative — what is the specific evidence that it poses less cancer cell dissemination risk than TURP in men with concurrent prostate cancer? Has that comparison been studied in this population?
Before Radiation
What are your rates of Grade 3 urinary toxicity, rectal toxicity, and erectile dysfunction at 5 and 10 years for patients with my tumor characteristics?
What is the documented risk of secondary bladder or rectal cancer from this treatment?
If ADT is being added to my radiation — what is the evidence for combining them at my specific risk group? What is the planned duration of ADT and what monitoring will be in place for bone density, cardiovascular function, and testosterone recovery?
If I develop biochemical recurrence after radiation, what are my treatment options and how do they compare to recurrence after surgery?
What is the evidence that proton beam therapy produces better outcomes than IMRT for my specific disease? (If at a proton center.)
Before Surgery
How many radical prostatectomies have you personally performed, and what are your personal patient outcome data on positive margin rates, urinary continence, and erectile function recovery?
Given my tumor location and stage, is bilateral nerve-sparing actually feasible? What happens to my erectile function probability if nerve-sparing is not possible on one or both sides?
What is the probability I will need adjuvant or salvage radiation after surgery? If so, what does that mean for my cumulative side effect burden?
Has active surveillance been discussed and ruled out for my specific risk level? On what basis?
Before Starting ADT
What is the evidence for starting ADT at my current disease stage? Is this for biochemical recurrence only (rising PSA), or is there evidence of clinical disease progression?
Given my cardiovascular history — has relugolix (Orgovyx, the oral option with lower cardiovascular event rates) been considered instead of Lupron?
What bone density monitoring will be in place? Will bone-protective medication be offered?
What is the evidence on ADT and dementia risk at the treatment duration being proposed?
What is the probability and timeline of testosterone recovery after stopping, at the duration of treatment being planned?
I understand this medication has a testosterone flare at initiation. Will anti-androgen coverage be provided for the first 2–4 weeks?
Active Surveillance — Evidence Base
Surgery — Radical Prostatectomy Outcomes
Radiation — Side Effects & Secondary Cancers
PSA & Overdiagnosis
ADT — Cardiovascular, Bone & Metabolic Effects
Biopsy — Infection & Oversampling Risk
Molecular Hydrogen Therapy
H2 vs. Oxygen Therapy — A Critical Distinction
Oxygen-based therapies (hyperbaric O2, ozone) increase tissue oxygen concentration — which drives production of superoxide and hydroxyl radicals (•OH), the most cytotoxic reactive oxygen species. This is the free radical risk inherent to oxygen therapies.
Molecular hydrogen (H2) works in the opposite direction. H2 selectively neutralizes •OH via a direct reaction: •OH + H₂ → H• + H₂O. The most destructive free radical is converted to water. H2 does not suppress beneficial signaling ROS — making it the only known antioxidant that targets •OH selectively without blunting the body's oxidative signaling or interfering with radiation and chemotherapy's tumor-killing mechanism.
Note: No peer-reviewed trials have studied molecular hydrogen specifically in prostate cancer populations as of 2026. Evidence is from cancer broadly and mechanistic research. H2 is not a treatment for prostate cancer — the evidence supports it as a supportive adjunct, particularly for men on radiation or chemotherapy where reducing treatment-associated oxidative damage is a documented clinical goal.